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Abstract  Evidence  on  effectiveness,  safety,  and  tolerability  of  imipenem/clavulanate  (IC)  and
linezolid containing  regimens  to  treat  multidrug-resistant  (MDR-)  and  extensively  drug-resistant
tuberculosis  (XDR-TB)  is  scarce.  The  aim  of  this  observational  study  is  to  evaluate  the  therapeu-
tic contribution  of  IC  and  linezolid  to  manage  MDR/XDR-TB  cases  at  the  reference  centre  of  São
Paulo state,  Brazil.  Twelve  patients  (9  males,  1  HIV  positive  in  antiretroviral  treatment,  4  MDR,
8 XDR)  were  treated  with  IC,  11  of  them  within  linezolid-containing  regimens.  They  all  were
previously  treated  with  treatment  failure,  for  a  median  (IQR,  interquartile  range)  of  4.5  (2--6.5)
times, having  a  severe  resistance  pattern  (median  number  of  resistances:  7  (5--8))  and  being
sputum smear  and  culture  positive.  IC  and  linezolid  were  prescribed  at  the  dose  of  1000  mg/day
and 600  mg/day,  respectively.  The  overall  exposure  was  (median  (IQR))  419  (375.5--658)  days
for IC  and  678  (392--720)  days  for  linezolid.  All  of  them  converted  their  sputum  (time  to  sputum
conversion;  60  (37.5--90)  days)  and  culture  (75  (60--135)  days),  and  7  were  cured  while  5  are
still on  treatment  with  a  gradually  improving  clinical  picture.
While  no  adverse  events  were  reported  for  IC,  2  minor  side  effects,  only,  were  attributed
to linezolid  (17%);  in  both  cases  the  drug  was  re-started  without  further  problems.  Our  study
suggests that  IC  and  linezolid-containing  regimens  can  be  used  safely  and  with  satisfactory
outcomes  in  reference  centres  to  treat  MDR/XDR-TB  patients.sa  de  Pneumologia.  Published  by  Elsevier  Espan˜a,  S.L.U.  This  is  an
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ntroduction
he  World  Health  Organization  (WHO)  estimated  over
80,000  new  multidrug-resistant  tuberculosis  (MDR-TB)
ases  with  190,000  deaths  occurring  in  2014.  While  overall
.7%  of  the  MDR-TB  strains  met  the  criteria  deﬁning  exten-
ively  drug  resistant  TB  (XDR-TB,  e.g.  resistance  to  at  least
ne  ﬂuoroquinolone  and  a  second  line-injectable  drug)  in
ome  countries  of  the  former  Soviet  Union  this  proportion  is
uch  higher  (29%  in  Belarus,  15%  in  Latvia).1--3
Treating  MDR-  and  XDR-TB  patients  with  the  drugs  avail-
ble  today  is  known  to  be  long,  expensive  and  complicated,
s  adverse  events  (AE)  are  frequent  and  often  severe.1--4
Presently  WHO  classiﬁes  second-line  anti-TB  drugs  into
ve  groups  favouring  their  stepwise  use  based  on  decreasing
fﬁcacy  and  safety  from  Group  1  to  5.  Recent  new  evidence
uggests  a  revision  of  the  present  classiﬁcation  might  be
ecessary.5
Clinicians  treating  MDR/XDR-TB  cases  often  face  difﬁ-
ulties  in  identifying  at  least  4  active  drugs  which  are
ecommended  by  WHO  to  compose  an  effective  multi-drug
egimen.1--5
Within  WHO  Group  5,  the  carbapenems  (meropenem,
mipenem,  ertapenem),  are  already  used  to  treat  MDR/XDR-
B  cases,  although  the  evidence  available  on  their  efﬁcacy,
afety,  and  tolerability  is  extremely  limited.1--7
Linezolid  is  also  used  to  treat  these  cases,  being  consid-
red  effective  but  often  difﬁcult-to-manage  because  of  its
requent  and  severe  AE.8
Evidence  on  the  combined  use  of  carbapenems  and  line-
olid  is  anecdotal.9
The  aim  of  the  present  study  is  to  evaluate  the  potential
linical  contribution  (effectiveness,  safety,  and  tolerability)
f  imipenem  clavulanate  (IC)-  and  linezolid-containing  regi-
ens  in  treating  a  cohort  of  MDR/XDR-TB  cases  at  a referral
ospital  in  Brazil.
aterial and methods
he  study,  observational  and  retrospective,  has  been  con-
ucted  in  the  São  Paulo  state  reference  centre,  Brazil,
ithin  a  joint  project  of  the  European  Respiratory  Soci-
ty  (ERS)  and  the  Brazilian  Thoracic  Society.  The  Centre  is
erved  by  a  quality-controlled  laboratory  belonging  to  the
HO  network.1 All  consecutive  MDR-TB  cases  (TB  caused  by
.  tuberculosis  strains  phenotypically  resistant  to  at  least
soniazid  and  rifampicin)  aged  ≥15  years  and  diagnosed  from
anuary  2013  to  December  2015  were  enrolled.
An  individualized  TB  regimen  was  administered  following
he  results  of  the  drug-susceptibility  test  (DST).1
The  attending  physician  prescribed  anti-TB  drugs  with-
ut  any  compelling  criteria  of  experimental  protocols  and,
onsequently,  blinding  or  randomized  methods  were  not  fol-
owed.
IC  was  administered  at  a  dose  of  1000  mg  1  time  per  day
lus  amoxicillin/clavulanic  acid  500/125  mg  three  times  a
ay  and  linezolid  at  the  dose  of  600  mg  per  day.A  standardized  ad-hoc  e-form  was  prepared  to  col-
ect  epidemiological  (i.e.,  duration  of  hospital  stay,  age,
lace  of  birth,  sex,  residence,  immigration  from  a  TB  high-
urden  country),  clinical  (i.e.,  HIV  status,  administration
g
i
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f  HIV  drugs,  previous  TB  diagnosis  and  treatment,  previ-
us  treatment  outcomes,  radiological  ﬁndings,  TB  therapy
nd  related  adverse  events,  duration  of  exposure  to  MC
nd  IC,  surgery,  sputum  smear  and  culture  positivity  at  the
reatment  baseline,  at  30,  60  and  90  days,  time  to  sputum
mear  and  culture  conversion,  WHO  treatment  outcomes),
nd  microbiological  (i.e.,  DST  results)  information  from  ofﬁ-
ial  medical  ﬁles.
Ethical  approval  for  the  collection  and  analysis  of  anony-
ous  and  retrospective  data  and  for  the  compassionate  use
f  the  drugs  is  not  necessary  according  to  the  Brazilian
aw.
esults
welve  patients  affected  by  pulmonary  TB  were  enrolled  at
 referral  hospital  in  São  Paulo  state  and  treated  with  IC,
hile  11  of  them  received  also  linezolid  (Tables  1  and  2).
Nine  were  males  (75%)  and  3  females,  with  a  median  (IQR)
ge  of  39.5  (27--43)  years.  A  single  patient  was  HIV  positive,
eing  in  regular  antiretroviral  treatment  with  a  combination
f  lamivudine,  efavirenz  and  tenofovir,  one  had  diabetes,
ne  hypertension,  2  were  admitted  with  acute  respiratory
ailure,  while  7  were  drug  abusers  and  4  alcohol  addicts
efore  admission.
Four  cases  met  the  deﬁnition  of  MDR-TB  and  8  of  XDR-TB.
They  all  were  previously  treated  (treatment  failure  being
he  last  outcome),  for  a  median  of  4.5  (2--6.5)  times.
The  cases  had  a  severe  resistance  pattern  (median  (IQR)
umber  of  resistance  7  (5--8))  and  were  sputum  smear  and
ulture  positive  when  referred  to  the  São  Paulo  State  Sec-
etary  of  Health.  All  of  them  had  cavities  in  the  chest
adiography,  being  bilateral  in  8  cases  (67%).
The  overall  exposure  was  (median  (IQR))  419
375.5--658))  days  for  IC  and  678  (392--720)  days  for
inezolid.  They  required  long  hospitalization  at  the
eference  Centre  (439.5  (403--669.5)  days).
All  of  them  converted  their  sputum  (time  to  sputum
onversion:  60  (37.5--90)  days)  and  culture  (75  (60--135)
ays),  and  7  (58%)  were  cured  while  5  are  still  on  treatment
ith  a  gradually  improving  clinical  picture.
While  no  adverse  events  were  reported  for  IC,  2  minor
nd  reversible  AEs  only  were  attributed  to  linezolid  (17%):
eripheral  neuropathy  in  patient  12  (linezolid  was  re-started
ithout  further  problems)  and  gastro-intestinal  disorders  in
atient  6  (diarrhoea,  managed  with  symptomatic  medica-
ions  without  need  to  stop  the  anti-TB  drugs).
iscussion
his  is  the  ﬁrst  study  reporting  bacteriological  conversion
nformation  and  treatment  outcomes  in  a  Latin  Ameri-
an  cohort  of  MDR/XDR-TB  cases  treated  with  IC  within
inezolid-containing  regimens.  A  single  patient  was  pre-
cribed  IC  but  not  linezolid  to  avoid  the  co-administration
ith  ethionamide  due  to  a  prior  history  of  peripheral
europathy.The  anti-TB  regimens  have  been  designed  as  per  WHO
uidelines  and  guided  by  drug  susceptibility  testing,  taking
nto  account  the  following:  (1)  kanamycin  was  not  avail-
ble  in  Brazil  and  capreomycin  was  available  after  2014;
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Table  1  Demographic  and  clinical  features  in  the  Brazilian  cohort.
Patient  Age  at  the
admission
(years)
Gender  Country  of
birth
HIV-positive
(ART)
Previous  exposure
to  anti-TB  therapy
Number  of  times
treated  >1  month
Pulm/
extrapulm-TB
Radiological
ﬁndings
Resistances  MDR/XDR-
TB
1  43  Male  Brazil  No  Yes 7  Pulmonary  Bilateral  pulmonary
involvement  with
cavitary  lesions
H,  R,  S,  Z,
Ofx,  Am,  Cm,
Km
XDR
2 24  Female  Brazil  No  Yes 6  Pulmonary  Bilateral  pulmonary
involvement  with
cavitary  lesions
H,  R,  S,  Ofx,
Am,  Cm,  Km
XDR
3 41  Male  Brazil  No  Yes 2  Pulmonary  Cavitary  lesions H,  R,  S,  Z,
Ofx,  Am,  Cm,
Km
XDR
4 42  Female  Brazil  No  Yes 10  Pulmonary  Bilateral  pulmonary
involvement  with
cavitary  lesions
H,  R,  S,  Z,
Ofx,  Am,  Cm,
Km
XDR
5 43  Male  Brazil  Yes
(Efz  +  3Tc  +  Tdf)
Yes 5  Pulmonary  Bilateral  pulmonary
involvement  with
cavitary  lesions
H,  R,  S,  Z,
Ofx
MDR
6 63  Male  Brazil  No  Yes 2  Pulmonary  Cavitary  lesions  H,  R,  E,  Z,
Ofx
MDR
7 38  Female  Brazil  No  Yes  2  Pulmonary  Bilateral  pulmonary
involvement  with
cavitary  lesions
H,  R,  Ofx,
Cm,
XDR
8 55  Male  Brazil  No  Yes  7  Pulmonary  Bilateral  pulmonary
involvement  with
cavitary  lesions
H,  R,  S,  E,  Z,
Ofx,  Am,  Cm,
Km
XDR
9 27  Male  Brazil  No  Yes  2  Pulmonary  Cavitary  lesions  H,  R,  E,  Z,
Ofx
MDR
10 18  Male  Brazil  No  Yes  3  Pulmonary  Bilateral  pulmonary
involvement  with
cavitary  lesions
H,  R,  S,  Ofx,
Am,  Cm,  Km
XDR
11 27  Male  Brazil  No  Yes  4  Pulmonary  Cavitary  lesions  H,  R,  E,  Z,
Ofx,
MDR
12 34  Male  Brazil  No  Yes  5  Pulmonary  Bilateral  pulmonary
involvement  with
cavitary  lesions
H,  R,  S,  E,  Z,
Ofx,  Km
XDR
MDR/XDR-TB: multidrug-resistant/extensively drug-resistant- tuberculosis; ART: anti- retroviral therapy; efz: efavirenz; 3tc: lamivudine; tdf: tenofovir. Drugs: H: isoniazid; R: rifampicin;
S: streptomycin; E: ethambutol; Z: pyrazinamide; Am: amikacin; Cm: capreomycin; Ofx: oﬂoxacin, Km: kanamycin.
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Table  2  Bacteriology,  treatment  and  outcome  in  the  Brazilian  cohort.
Patient  Prescribed
regimen
Length  of
hospital  stay
(days)
Months  of
treatment
after  MDR-TB
diagnosis
Sputum  smear
conversion
(days)
Sputum
culture
conversion
(days)
Linezolid
dose
Interruption of
Linezolid  due
to  adverse
events
AEs
presumably
due to
Linezolid
Total
linezolid
exposure
(days)
Imipenem
dose
Interruption  of
Imipenem  due
to  AEs
AEs  pre-
sumably
due  to
Imipenem
Total
Imipenem
exposure
(days)
Treatment
outcome
1  Am  +  Mfx  +  Eto  +
Trd  +  Ipm  +  Amx/
Clv  +  Lzd  +  Clr  +  E
720 114  30  40  600  mg/day  No  No  720  1000  mg/day  No  No  720  Cured
2  Cm  + Mfx  + Eto  +
Trd  +  Ipm  +  Amx/
Clv  +  Lzd  +  Clr  +
E  +  Z
720 87  60  60  600  mg/day  No  No  720  1000  mg/day  No  No  720  Cured
3  S  +  Mfx  +  Eto  +
Trd  +  Ipm  +  Amx/
Clv  +  Lzd  +  Clr  +  E
453 40  60  90  600  mg/day  No  No  720  1000  mg/day  No  No  455  Cured
4  Am  +  Mfx  +  Eto  +
Trd  +  Ipm  +  Amx/
Clv  +  Lzd  +  Clr  +
E  +  Z
227 85  45  15  600  mg/day  No  No  720  1000  mg/day  No  No  227  Cured
5  Am  +  Mfx  +  Eto  +
Trd  +  Ipm  +  Amx/
Clv  +  Lzd  +  Clr  +  E
660 23  180  180  600  mg/day  No  No  638  1000  mg/day  No  No  638  Cured
6  Am  +  Mfx  +  Eto  +
Trd  +  Ipm  +  Amx/
Clv  +  Lzd  +  Clr  +
E  +  Cfz
415 18  60  60  600  mg/day  No  Gastro-
intestinal
disorders
(reversible)
392  1000  mg/day  No  No  392  Still  on
treatment
7  S  +  Mfx  +  Eto  +
Ipm  +  E  +  Clr  +  Z
575 39  60  150  --  --  --  --  1000  mg/day  No  No  362  Cured
8  Mfx  +  Eto  + Ipm  +
Lzd  +  Clr  +  E  +  Z
679 71  30  180  600  mg/day  No  No  678  1000  mg/day  No  No  678  Still  on
treatment
9  Am  +  Mfx  +  Eto  +
Ipm  +  Lzd  +  Z  + Cfz
391 7  30  60  600  mg/day  No  No  389  1000  mg/day  No  No  389  Still  on
treatment
10  Am  +  Mfx  +  Eto  +
Ipm  +  Lzd  +  Clr  +
E  +  Z  +  Cfz
419 14  120  120  600  mg/day  No  No  418  1000  mg/day  No  No  418  Still  on
treatment
11  Mfx  +  Eto  + Trd  +
Ipm  +  Amx/Clv  +
Lzd  +  Z
426  44  120  120  600  mg/day  No  No  725  1000  mg/day  No  No  420  Cured
12  Cm  + Mfx  + Eto  +
Trd  +  Ipm  +  Amx/
Clv  +  Lzd  +  Clr  +  E  +
Z  +  Cfz
120 46  60  60  600  mg/day  Yes  Peripheral
neuropathy
(reversible)
105  1000  mg/day  No  No  123  Still  on
treatment
AE: adverse event. Drugs: S: streptomycin; Z: pyrazinamide; E: ethambutol; Am: amikacin; Mfx: moxiﬂoxacin; Eto: ethionamide; Trd: terizidone; Ipm: imipenem; Amx/Clv: amoxi-
cilin/clavulanate; Lzd: linezolid; Clr: claritromycin; Cm: capreomycin; Cfz: clofazimine; Ipm: imipenem.
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(2)  pyrazinamide  was  not  used  when  intolerance  to  it  was
documented;  (3)  terizidone  is  used  in  Brazil  instead  of
cycloserine;  and  (4)  PAS  (para-aminosalicylic  acid)  has  been
made  available  in  Brazil  after  2014.
The  results  of  our  study  demonstrate  that,  in  spite  of
the  cases  severity,  IC  within  linezolid  containing  regimens
is  able  to:  (1)  ensure  sputum  smear  and  culture  conversion
in  all  the  cases  of  the  cohort,  with  time  to  bacteriological
conversion  similar  to  that  recently  described  by  the  Inter-
national  Carbapenems  Study  Group1--3;  (2)  reach  a  positive
treatment  outcome  in  7  out  of  12  cases,  while  the  remaining
5  are  improving  clinically  and  radiologically  and  remain  con-
sistently  sputum  smear  and  culture  negative;  and  (3)  is  safe,
if  managed  at  reference  centre  level,  with  two  minor  and
reversible  AEs.
Based  on  its  molecular  mechanism  of  action,  imipenem  is
more  active  than  meropenem.1,3 However,  this  does  not  nec-
essarily  translate  into  better  clinical  results,  as  shown  in  a
recent  multinational  study.3 Furthermore,  the  study  results
conﬁrm  the  importance  of  prescribing  imipenem  in  associ-
ation  with  clavulanate  (a  -lactamase  inhibitor)  which  can
inhibit  the  activity  of  the  potent  -lactamase,  encoded  by
the  BlaC  gene.1--3
The  observational  and  retrospective  design  of  the  study
has  in-built  limitations  (impossibility  to  pre-calculate  the
sample  size,  to  have  a  control  group,  to  randomize  and
ensure  blindness).
Additional  limitations  are  the  small  sample  size  (with
limited  inclusion  of  patients  with  HIV  co-infection)  and  the
fact  that  these  patients  received  several  prior  anti-TB  drugs.
However,  the  study  is,  as  of  today,  the  third  in  the  litera-
ture  (the  ﬁrst  in  Latin  America)  and  this  anecdotal  evidence
might  be  of  help.
In  conclusion,  the  study  results  conﬁrm  that  IC,
within  the  carbapenems  class  of  drugs  might  have  a
role  in  treating  MDR/XDR-TB  and  that  IC  and  linezolid-
containing  regimens  can  be  used  safely  and  with  satisfactory
outcomes  in  reference  centres  to  treat  MDR/XDR-TB
patients.9,10
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